New drug targets brain inflammation in early Alzheimer's – could it slow memory loss?

NCT ID NCT05318976

Completed Disease control Sponsor: Inmune Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 30, 2026 · Last updated Apr 28, 2026 · Updated 4 times

Summary

This study tested an experimental drug called XPro1595 in 208 people with early Alzheimer's disease who also had signs of brain inflammation. The goal was to see if the drug could improve thinking, memory, and daily function compared to a placebo over 24 weeks. Researchers also checked for safety and changes in brain health markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

INmune Bio Investigational Site

Darlinghurst, New South Wales, 2010, Australia
INmune Bio Investigational Site

Macquarie Park, New South Wales, 2113, Australia
INmune Bio Investigational Site

Adelaide, South Australia, 5011, Australia
INmune Bio Investigational Site

Box Hill, Victoria, 3128, Australia
INmune Bio Investigational Site

Carlton, Victoria, 3053, Australia
INmune Bio Investigational Site

Ivanhoe, Victoria, 3079, Australia
INmune Bio Investigational Site

Parkville, Victoria, 3050, Australia
INmune Bio Investigational Site

Nedlands, Western Australia, 6009, Australia
INmune Bio Investigational Site

Kelowna, V1Y 1Z9, Canada
INmune Bio Investigational Site

Ottawa, K1Z 1G3, Canada
INmune Bio Investigational Site

Sherbrooke, J1L 0H8, Canada
INmune Bio Investigational Site

Toronto, M3B 2S7, Canada
INmune Bio Investigational Site

Toronto, M4G 3E8, Canada
INmune Bio Investigational Site

West Vancouver, V7T 1C5, Canada
INmune Bio Investigational Site

Brno, 60200, Czechia
INmune Bio Investigational Site

Pilsen, 30100, Czechia
INmune Bio Investigational Site

Prague, 10000, Czechia
INmune Bio Investigational Site

Prague, 16000, Czechia
INmune Bio Investigational Site

Rychnov nad Kněžnou, 51601, Czechia
INmune Bio Investigational Site

Bron, 69500, France
INmune Bio Investigational Site

Nantes, 44800, France
INmune Bio Investigational Site

Toulouse, 31059, France
INmune Bio Investigational Site

Berlin, 10629, Germany
INmune Bio Investigational Site

Chemnitz, 09111, Germany
INmune Bio Investigational Site

Bialystok, 15-756, Poland
INmune Bio Investigational Site

Bydgoszcz, 85-133, Poland
INmune Bio Investigational Site

Wroclaw, 53-659, Poland
INmune Bio Investigational Site

Barcelona, 08028, Spain
INmune Bio Investigational Site

Barcelona, 08222, Spain
INmune Bio Investigational Site

Córdoba, 14004, Spain
INmune Bio Investigational Site

Madrid, 28006, Spain
INmune Bio Investigational Site

Seville, 41009, Spain
INmune Bio Investigational Site

Valencia, 46017, Spain
INmune Bio Investigational Site

Valencia, 46026, Spain
INmune Bio Investigational Site

Birmingham, B16 8LT, United Kingdom
INmune Bio Investigational Site

Bristol, BS32 4SY, United Kingdom
INmune Bio Investigational Site

Guildford, GU2 7YD, United Kingdom
INmune Bio Investigational Site

London, W1G 9JF, United Kingdom
INmune Bio Investigational Site

Motherwell, ML1 4UF, United Kingdom
INmune Bio Investigational Site

Plymouth, PL7 8BT, United Kingdom
INmune Bio Investigational Site

Winchester, S021 1HU, United Kingdom

Conditions

Explore the condition pages connected to this study.

ALZHEIMER DISEASE BRAIN DISEASES CENTRAL NERVOUS SYSTEM DISEASES DEMENTIA MENTAL DISORDERS MILD COGNITIVE IMPAIRMENT NERVOUS SYSTEM DISEASES NEUROCOGNITIVE DISORDERS NEUROCOGNITIVE DISORDERS NEURODEGENERATIVE DISEASES TAUOPATHIES